- Home
- IDE vs FBRX Comparison
IDE vs FBRX Comparison
Compare IDE & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDE
- FBRX
- Stock Information
- Founded
- IDE 2010
- FBRX N/A
- Country
- IDE United States
- FBRX United States
- Employees
- IDE N/A
- FBRX N/A
- Industry
- IDE Finance/Investors Services
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- IDE Finance
- FBRX Health Care
- Exchange
- IDE Nasdaq
- FBRX Nasdaq
- Market Cap
- IDE 187.9M
- FBRX 154.5M
- IPO Year
- IDE N/A
- FBRX N/A
- Fundamental
- Price
- IDE $12.44
- FBRX $10.56
- Analyst Decision
- IDE
- FBRX Strong Buy
- Analyst Count
- IDE 0
- FBRX 3
- Target Price
- IDE N/A
- FBRX $68.00
- AVG Volume (30 Days)
- IDE 33.5K
- FBRX 69.5K
- Earning Date
- IDE 01-01-0001
- FBRX 08-14-2025
- Dividend Yield
- IDE 8.83%
- FBRX N/A
- EPS Growth
- IDE N/A
- FBRX N/A
- EPS
- IDE N/A
- FBRX N/A
- Revenue
- IDE N/A
- FBRX N/A
- Revenue This Year
- IDE N/A
- FBRX N/A
- Revenue Next Year
- IDE N/A
- FBRX N/A
- P/E Ratio
- IDE N/A
- FBRX N/A
- Revenue Growth
- IDE N/A
- FBRX N/A
- 52 Week Low
- IDE $8.61
- FBRX $4.11
- 52 Week High
- IDE $10.46
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- IDE 62.34
- FBRX 43.42
- Support Level
- IDE $12.26
- FBRX $10.65
- Resistance Level
- IDE $12.46
- FBRX $11.57
- Average True Range (ATR)
- IDE 0.10
- FBRX 0.85
- MACD
- IDE -0.01
- FBRX -0.09
- Stochastic Oscillator
- IDE 65.52
- FBRX 18.83
About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest
Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).